Chesnara Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Visual. Strategic. Ready to download.
This BCG Matrix snapshot for Chesnara's life and pensions portfolios maps product lines across market-growth and relative market-share, identifying Stars to scale, Cash Cows to optimise returns, Question Marks that require decisive investment choices, and Dogs for potential run-off or disposal. The concise preview outlines strategic implications for capital allocation and portfolio rationalisation across Chesnara's mature UK, Netherlands and Swedish books. Purchase the full BCG Matrix report for quadrant-level placements, data-driven recommendations, and deliverables in Word and Excel to guide investment and management decisions.
Stars
Dutch Open Business Expansion
The Scildon brand in the Netherlands is Chesnara's key growth engine in open life insurance, growing APE (annual premium equivalent) 12% year-on-year to €82m by Q3 2025 and lifting group new business value by €18m. The segment benefits from three product launches in 2024-25 and a broker network covering 65% of Dutch independent advisers, boosting market share to ~4.2%. It needs ongoing capital-Chesnara allocated €45m to Dutch expansion in 2025-but remains a market leader on product innovation and distribution.
Movestic Unit Linked Pensions
Movestic Unit Linked Pensions in Sweden is a star: high market growth from ageing demographics and 2019-2020 pension reforms lifted unit-linked assets to SEK 48bn by 2024, with Movestic growing new business value ~18% YoY in 2023-24.
The unit holds strong market share in digital advice and platforms, so Chesnara should reinvest-estimated SEK 200-300m over 2025-26-to keep tech leadership and sustain an ROCE above group average.
Strategic M&A Execution
Chesnara has become a premier consolidator, completing over 15 deal transactions since 2018 and adding £3.2bn in assets under management (AUM) in 2024 alone, which positions new portfolios as Stars during initial integration.
These Stars typically boost group AUM growth rates by 12-18% in the first 12-24 months as migration and pricing synergies materialize.
The firm's deal pipeline averaged £1.1bn of target value in 2024, showing repeat ability to identify high-value targets in a consolidating UK and European closed-book market.
Sustainable Investment Portfolios
Chesnara's Sustainable Investment Portfolios have captured circa 18% of its new fund inflows in 2024, reflecting a broader 22% annual growth in UK green finance; aligning portfolio mandates with ESG rules (UK FCA guidance 2023) drove £320m of net inflows and improved retention versus legacy funds.
This high-growth segment needs active promotion and distribution support-additional marketing and placement could raise AUM by 35% over 3 years-while positioning Chesnara for long-term leadership in green annuity investments.
- 2024 net inflows £320m
- 18% share of Chesnara new inflows
- UK green finance grew 22% in 2024
- Potential AUM +35% in 3 years with promotion
Digital Policy Administration Platforms
Investment in proprietary digital policy administration platforms has let Chesnara deliver faster quotes and 24/7 policy access, aiding a 12% year-on-year digital channel growth and a 3ppt rise in retention to 78% in 2024.
These platforms are capturing market share as customers demand transparency; 46% of policyholders now check policy data weekly, lifting online renewals by 18% in 2024.
Continued funding is critical: a £30-40m incremental R&D run-rate over 2025-27 would accelerate API integrations and AI claims automation to meet industry standards.
- 12% YoY digital growth
- 78% retention (2024)
- 46% weekly policy checks
- £30-40m recommended R&D (2025-27)
Strong growth across Scildon, Movestic, M&A and sustainable funds-reinvest to lead
Stars: Scildon NL (APE €82m, +12% YoY; €45m capex 2025), Movestic SE (unit-linked SEK48bn, NBV +18% YoY), M&A pipeline (£1.1bn avg 2024; AUM +£3.2bn 2024), Sustainable funds (£320m net inflow 2024; 18% new inflows). Reinvest to sustain ROCE and tech/distribution leadership.
| Segment | Key metric | 2024-25 figure |
|---|---|---|
| Scildon NL | APE / Capex | €82m / €45m |
| Movestic SE | Unit-linked assets / NBV growth | SEK48bn / +18% YoY |
| M&A | Pipeline / AUM added | £1.1bn / +£3.2bn |
| Sustainable funds | Net inflows / share | £320m / 18% |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Chesnara's portfolio with quadrant-specific strategies, investment recommendations, and trend-based risk insights.
Customizable Excel Spreadsheet
One-page Chesnara BCG Matrix placing each business unit in a quadrant for quick strategic clarity
Cash Cows
Countrywide Assured UK Books
The Countrywide Assured UK closed books remain Chesnara's cash cow, generating steady premiums and investment income from a mature portfolio worth about £3.1bn of IFRS liabilities at H1 2025 and yielding ~8% ROE on releaseable surplus.
Closed-book status cuts new-business costs-administration and reinsurance run at low single-digit percentages of revenue-so net cash generation funded dividends of £58m in FY 2024 and underpins the group's 2025 payout policy.
Waard Group Closed Portfolios
Operating in the Netherlands, Waard Group Closed Portfolios manages mature life and funeral policies with high efficiency and near-zero premium growth, generating predictable operating margins around 18% in 2024 and ROE near 12%.
The unit produced a surplus capital release of €210m in FY2024, exceeding required capital by ~25%, and provided liquidity to fund Chesnara's UK and Ireland expansion.
Legacy Life Assurance Policies
Chesnara's Legacy Life Assurance Policies are mature across the UK, Ireland, and Gibraltar, representing about £4.1bn of in-force reserves as of FY 2024 and delivering high margin cash flows from closed-book annuities and with-profits funds.
These portfolios show operating margins above 30% in 2024 thanks to scale efficiencies and lower acquisition costs, requiring minimal marketing so capital release-£120m returned to shareholders in 2024-can be prioritised.
Solvency II Capital Surpluses
Chesnara maintains a strong Solvency II surplus-EUR 1.05bn of eligible own funds over the SCR at 31 Dec 2024-acting as a financial reservoir for the group.
This capital surplus stems from mature cash-generative business units that consistently produce free cash flow above required reinvestment, funding debt service and returns.
It also underwrites targeted investment into question mark products, with up to EUR 120m allocated for new product development in 2025.
- Solvency II surplus: EUR 1.05bn (31 – Dec – 2024)
- Free cash flow drivers: mature UK annuity and protection books
- 2025 R&D/allocation for question marks: EUR 120m
Fixed Annuity Portfolios
Fixed annuity portfolios deliver steady yields from long-term contracts, generating about 4.2% annualized income in 2025 and underpinning Chesnara's capital stability with predictable cash flows that fund dividends and buybacks.
In the mature 2025 market these assets need minimal active management versus equities or credit, lowering operating risk and freeing capital for higher-growth units.
They form the backbone of Chesnara's payout capacity, supporting a 2025 dividend coverage ratio near 1.1x and stable shareholder returns.
- 4.2% est. annuity yield (2025)
- Low management intensity vs equities
- Dividend coverage ≈1.1x (2025)
- Reliable long-term cash flow
Chesnara's £7.2bn cash cows fuel £178m returns and €1.05bn Solvency II buffer
Chesnara's cash cows-Countrywide Assured UK, Waard closed portfolios, and legacy life books-generated free cash flow from ~£7.2bn combined in-force reserves (FY2024/H1 – 2025), funded £178m shareholder returns in 2024, and kept Solvency II surplus at EUR 1.05bn (31 – Dec – 2024), supporting a 2025 dividend coverage ≈1.1x.
| Metric | Value |
|---|---|
| In – force reserves | ≈£7.2bn |
| Solvency II surplus | EUR 1.05bn (31 – Dec – 2024) |
| Shareholder returns 2024 | £178m |
| Annuity yield 2025 | 4.2% |
| Dividend coverage 2025 | ≈1.1x |
Preview = Final Product
Chesnara BCG Matrix
The document you're previewing is the exact Chesnara BCG Matrix you'll receive after purchase-no watermarks, no placeholders, just a fully formatted, analysis-ready report crafted for strategic clarity. This preview mirrors the downloadable file and requires no revisions: designed by experienced strategists, it's ready for editing, printing, or presenting to stakeholders. Purchase grants immediate access to the professional BCG Matrix for seamless integration into your planning and reporting.
Dogs
Small Scale Legacy IT Systems
Older, fragmented IT systems handling minor policy blocks drain Chesnara via high maintenance: legacy platforms can cost 15-25% more to operate than modern cloud setups, eating into margins on low-premium lines that show near-zero growth.
These Dogs have low technological market share-few integrations, limited API support-and often require capital spends that exceed expected returns, with decommissioning studies at peers showing payback under 3 years if retired.
Management flags them as cash-trap risks; removing 5-10 such systems could cut annual IT spend by an estimated 8-12% and reallocate capital to digital underwriting and claims automation.
Discontinued Protection Product Lines
Certain older Chesnara protection lines, discontinued to new sales, now sit in low-share, low-growth areas: estimated UK individual protection premiums for these vintage books fell ~35% from 2018-2023, underperforming group growth and shrinking by ~5% CAGR. They typically break even-operating margins near 0-2% in FY2024-but add little to strategic earnings per share or capital allocation priorities.
Underperforming Niche Swedish Funds
Within Sweden, niche equity and sector funds averaging assets under management of SEK 150-400m in 2024 show median 3-year AUM decline of 8% and trailing annualized return of 2.1%, well below large peers (FTSE All-Share Sweden 7.4%).
Low growth and no scale-driven fee advantage leave margins under 40bps, making these funds logical consolidation or divestiture targets to cut costs and reallocate resources.
They absorb 15-25% of product-team time despite representing ~6% of total firm AUM, diverting effort from star funds that generate 70% of net inflows.
High Cost Low Volume Closed Books
Small closed books acquired years ago, typically under 50k policies, are classed as Dogs for Chesnara; average per-policy admin costs exceed 120 in 2024 pounds, cutting net margin to single digits and contributing under 3% of group cash flow in 2024.
Without consolidation or a sale, these portfolios-often loss-making after admin and reserving-will remain a drag on ROE and cash generation; a targeted remediation or bulk transfer is needed to stop continued margin erosion.
- Typical size: <50,000 policies
- Per-policy admin cost: >£120 (2024)
- Contribution to group cash flow: <3% (2024)
- Impact: depresses ROE and adds fixed overhead
Traditional Endowment Policies
Traditional endowment policies sit in Chesnara's Dogs quadrant: the UK market has shrunk ~85% since 2000, with new sales near zero and in-force volumes declining ~6% annually; these contracts yield single-digit returns and face intense PRA/FCA regulation, so they offer low cash generation and little case for reinvestment.
- Low growth: new sales ≈0 by 2024
- Shrinking base: in-force down ~6% p.a.
- Low returns: single-digit ROE contribution
- High scrutiny: PRA/FCA capital pressure
Chesnara under pressure: high admin costs, weak returns-consolidation could revive ROE
Closed, low-growth protection and fund books drain Chesnara:
per-policy admin >£120 (2024), <3% group cash flow, margins near 0-2%, small funds AUM SEK150-400m with 3yr returns 2.1% (2024), UK vintage premiums down ~35% (2018-2023); consolidation or sale could cut IT/admin spend 8-12% and lift ROE.
| Metric | Value |
|---|---|
| Per-policy admin (2024) | £>120 |
| Group cash flow share (2024) | <3% |
| Vintage premiums change (2018-2023) | -35% |
| Small funds 3yr return (2024) | 2.1% |
| Potential IT/admin savings | 8-12% |
Question Marks
New European Market Entry
Chesnara eyeing Germany and Iberia as Question Marks: these markets grew life & pensions premiums 6-8% CAGR 2019-24 (Germany ~€100bn 2024), yet Chesnara holds near-zero share, so revenue upside exists but is unproven.
Establishing footholds needs heavy capex and M&A: typical EU tuck-in deals cost €50-200m; initial integration and regulatory capital could tie up £100-250m over 3 years.
Payback uncertain-projected IRR under base case ~8-10% over 7-10 years versus Chesnara group WACC ~7%-so market entry remains a high-risk, high-reward Question Mark.
Direct to Consumer Digital Apps
The Direct-to-Consumer digital apps are a clear Question Mark: Chesnara launched its D2C platforms in 2024 targeting under-45s, a segment where UK mobile insurance engagement rose 18% in 2023, but app MAUs remain under 50k and CAC (customer acquisition cost) is ~£120-pressing cash flow while LTV is unproven.
Bulk Purchase Annuity Small Schemes
The small-scheme bulk purchase annuity (BPA) market grew ~14% in 2024 to £18.5bn as corporates de-risk; demand from schemes under £100m has risen 22% year-on-year. Chesnara holds low single-digit share in this niche versus Aviva, Legal & General and Rothesay, so it faces intense competition. To reach star status Chesnara would need to deploy roughly £500-700m of incremental capital and scale premiums by ~3x within 3 years.
Third Party Administration Services
Chesnara's Third Party Administration (TPA) service is a Question Mark: the platform-as-a-service model targets high growth in outsourced insurance admin, but in 2024 TPA revenues were under 2% of group income (£<100m est.), needing heavy marketing and sales investment to scale.
It must demonstrate client wins vs incumbents like Capita and DXC, show double-digit annual revenue growth, and reach mid-single-digit operating margin to shift toward Star.
- 2024 revenue share: <2% (~£<100m est.)
- Required growth: 20%+ CAGR to scale
- Target margin: mid-single-digit to 10%+
- Main competitors: Capita, DXC, Cognizant
Innovative Health and Wellness Riders
Innovative health and wellness riders, trialed in the Netherlands and Sweden since 2024, sit in Chesnara's Question Marks quadrant: early-stage add-ons for life policies with buyer awareness under 20% in pilot cohorts and expected take-up rates of 5-12% in year one.
They need targeted marketing-estimated €0.8-1.5m annual spend per market-to lift adoption above the 15% threshold that avoids Dog status; without this, low premium contribution (projected <2% of group revenue in 2025) risks divestment.
- Pilots: Netherlands, Sweden (2024-25)
- Initial awareness: <20%
- Projected year – 1 take-up: 5-12%
- Required marketing: €0.8-1.5m/market
- Revenue impact if low adoption: <2% of 2025 group revenue
Chesnara Growth Gaps: Germany/Iberia, D2C & TPA-Capital, LTV & Scale Needed
Chesnara Question Marks: Germany/Iberia (6-8% CAGR 2019-24; Germany ~€100bn premiums 2024; near-zero share); D2C apps (MAU <50k; CAC ~£120); small-scheme BPA (market £18.5bn 2024; Chesnara low single-digit share; needs £500-700m); TPA (<2% group rev ~£<100m est.; needs 20%+ CAGR); health riders (pilot awareness <20%; year – 1 take-up 5-12%).
| Segment | Key metric | Need |
|---|---|---|
| Germany/Iberia | 6-8% CAGR; €100bn | Market entry capex/M&A |
| D2C | MAU<50k; CAC £120 | Improve LTV |
Frequently Asked Questions
It provides a presentation-ready breakdown of Chesnara across the BCG quadrants with clear strategic context. The template is designed for investor-ready analysis, so you can quickly see where the company's closed-book life and pensions segments fit, and use the structured framework to guide capital allocation and portfolio decisions without building the analysis from scratch.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.